A new and more infectious strain of the Covid-19 coronavirus has spread to more countries around the globe. But what’s different about this new pathogen? And should people be prepping for a total apocalypse yet?
Ireland confirmed the presence of a new and highly infectious coronavirus strain on Friday, while authorities in Lebanon and Japan also recorded the first cases attributed to this variant. In continental Europe, Germany and Denmark confirmed the presence of the strain earlier this week, joining the Netherlands and Italy.
Little is yet known about the new strain – which bears the catchy name ‘SARS-CoV-2 VOC 202012/01.’ But while it certainly poses a problem, it does not appear as apocalyptic as some media have been presenting it.
Where did it come from?
The new strain is believed to have originated in the UK, and was first detected there in September. It spread rapidly, and testing data from UK laboratories show that in certain areas, it now accounts for more than two thirds of all cases of Covid-19.
The rapid spread of the new strain prompted British Prime Minister Boris Johnson to reimpose harsh restrictions on large swathes of the country, effectively cancelling Christmas for millions of Londoners and others in the southeast. More than 50 countries have banned travel to and from the UK, but with virologists predicting an upsurge of discoveries in new countries in the coming days, the EU has called on its members to lift their restrictions on UK travel.
What’s new about it?
The main factor setting the new strain apart from its predecessor is its infectiousness. Although pinning down exactly how much more transmissible is difficult, PM Johnson has repeatedly claimed the strain is 70 percent more infectious than the existing strain, apparently quoting physicians from Imperial College London and the government’s own New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG).
With the government floating such ominous figures, the media went into overdrive. The Sun described the new strain as a “nightmare before Christmas,” while Metro called it “Mutant Covid.” Even the more restrained Financial Times said that scientists are “alarmed” at the spread of the “Covid mutant.”
However, the evidence for increased transmissibility is still scant, and some dissenting doctors reckon there’s no proof of the new strain spreading faster at all. “We have not seen any evidence to back that claim up,” Professor of microbiology Hugh Pennington told the Scottish Sun this week. Others, including German virologist Christian Drosten, have said there is still not enough data to conclude whether the new strain is indeed more transmissible.
Some specific claims about the new strain have also emerged, for instance that it transmits easier between children. Professor Neil Ferguson of NERVTAG made this claim earlier this week, but added that “more research would need to be done on the matter before any conclusions should be drawn.”
What threat does it pose?
On the surface, the idea of a mutated virus may spark alarm. However, the coronavirus variant prevalent before this new strain was itself a mutation of the original pathogen that emerged in Wuhan, China, a year ago. Upon reaching Europe in February the virus mutated into a strain known as ‘D614G,’ which then became the dominant strain worldwide. Another strain, A222V, broke out in Spain shortly afterwards and now accounts for up to seven percent of samples in Europe.
When ‘D614G’ emerged, scientists warned that it could be nine times as contagious as the Wuhan strain. Thankfully, this warning has never been proven to be the case.
All viruses mutate, usually becoming milder as they do. World Health Organization emergencies chief Mike Ryan told a virtual briefing this week that such mutations are “a normal part of virus evolution.”
Even with the threat of further mutations, though, scientists in the UK are trialling an experimental cocktail of antibodies that they say could stop anyone exposed to the coronavirus from going on to develop Covid-19. Developed by University College London Hospitals and British-Swedish drug firm AstraZeneca, the treatment promises to confer instant immunity on anyone exposed to the pathogen. Vaccines, on the other hand, can take up to a month to confer full immunity.